Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Manufacture Facilities, Quality & Compliance, Contract Manufacturing Services, Bioprocessing - Single Use Systems

Adapt or Get Annexed?

Incoming amendments to Annex 1 of the EU’s Good Manufacturing Practice (GMP) are set to bring major changes to how drug developers and their CDMO partners handle, process, and manufacture sterile products (1, 2). The uncertainty hovering over the final draft is a daunting prospect for many, with many drug developers hesitant to upgrade their facilities without knowing if their new infrastructure will be compliant.

However, some changes look highly likely, so developers can at least start making some steps to ensure new sterile facilities are fit for compliance before the new regulations come into effect.

What can we expect? One change includes a requirement for pharma companies to implement a “Contamination Control Strategy” (CCS) across cleanroom zones when handling and manufacturing sterile products. And that requires a documented approach to contamination control – minimizing interactions across technical, organizational, and procedural contamination control measures. It’s also expected that manufacturers will need to carry out a comprehensive risk assessment and implement new methods for monitoring integrity across production lines. 

For example, current Annex 1 guidelines require all connections for aseptic processing to be performed under highly classified Grade A environments. However, the latest revision acknowledges recent advancements in sterile processing technology, such as restricted access barriers systems, isolators, robotic systems, rapid microbial testing and monitoring systems, that can help minimize potential contamination in the surrounding environment. Provided that the connection device has been appropriately validated to show no ingress of microbial contamination – and that a CCS has been conducted – transfers could be performed in lower-classified environments. 

Although the new guidelines factor in the sterility benefits of new technology, many organizations may not have them in place. These companies will need to adhere to previous guidelines, and the requirement for more stringent classification measures around product transfer. When it comes to implementing the detailed CSS that is likely to be included in the Annex amends, my advice is to start planning documentation procedures now. And if you think new solutions will be required to close sterility gaps, again starting early will be key – particularly as equipment availability has been impacted by new or ongoing COVID-19 disruptions.

As pharma companies look to source any necessary new technologies, those that opt for reusable production line components will also need to consider the cleaning and verification processes required to assure sterility between each transfer. Single-use technologies (SUTs) are increasingly used on production lines and could help to ensure compliance. For example, SUT transfer bags and SBVs make it easier to maintain sterility across powder transfers. 

Continuing the theme of elimination, the new draft of Annex 1 focuses on removing operators from production line processes to reduce the risk of contamination. The implementation of smart factory technology (SFT) could be one means to achieve this. For example, manufacturers could consider augmenting  their facilities with mechanical handling devices that allow for handsfree moving, lifting, inverting, and docking of product containers and SBVs, reducing reliance on operator intervention.

SFTs can also monitor the health of production line components and identify where maintenance is required without affecting aseptic integrity – all while providing a fully documented audit trail. By removing the need for manual monitoring of production line equipment, manufacturers could boost efficiency, narrow the scope for human error, and reduce contamination risks. 

In my view, rather than playing the waiting game, industry players should take a proactive approach to future compliance. The new Annex 1 draft serves as a detailed roadmap for the requirements pharma companies in the EU must follow to remain compliant. By spending time and resources on new technologies and processes now, you could avoid a last minute rush to meet the new rules. 

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. EU Commission, “EU GMP Annex 1 Revision: Manufacture of Sterile Medicinal Products (Draft)”, gmp-compliance.org (2020). Available at: https://bit.ly/An1-Revis
  2. EU Commission, “Annex 1 – Manufacture of Sterile Medicinal Products”, European Union (2017). Available at: https://bit.ly/An1-PDF
About the Author
Christian Dunne

Christian Dunne, Head of Sterility Assurance at Chargepoint Technology, UK

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register